| Market Cap | 3.61M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -22.39M | Forward P/E | -0.43 | EPS next Y | - | 50D Avg Chg | -14.00% |
| Sales | 1.96M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -67.00% |
| Dividend | N/A | Price/Book | 0.35 | EPS next 5Y | - | 52W High Chg | -96.00% |
| Recommedations | 3.00 | Quick Ratio | 0.02 | Shares Outstanding | 8.36M | 52W Low Chg | 10.00% |
| Insider Own | 8.06% | ROA | -43.25% | Shares Float | 1.12M | Beta | -0.66 |
| Inst Own | 0.06% | ROE | - | Shares Shorted/Prior | 13.44K/31.05K | Price | 0.59 |
| Gross Margin | -77.27% | Profit Margin | - | Avg. Volume | 129,282 | Target Price | - |
| Oper. Margin | -5,526.11% | Earnings Date | Nov 12 | Volume | 48,502 | Change | -3.31% |
OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland.
| HC Wainwright & Co. | Neutral | Aug 14, 23 |
| HC Wainwright & Co. | Buy | Jul 20, 23 |
| HC Wainwright & Co. | Buy | Jun 26, 23 |
| HC Wainwright & Co. | Buy | Jun 21, 23 |
| HC Wainwright & Co. | Buy | May 16, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bacher Johannes | Chief Operating Offi.. Chief Operating Officer | Mar 02 | Option | 0.00 | 21,250 | 81,250 | 03/04/22 | |
| Schacht Oliver | Chief Executive Offi.. Chief Executive Officer | Mar 02 | Option | 0.00 | 38,750 | 68,750 | 03/04/22 | |
| Bacher Johannes | Chief Operating Offi.. Chief Operating Officer | Jan 26 | Buy | 0.85 | 25,000 | 21,250 | 60,000 | 01/27/22 |